Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase

Journal of Medicinal Chemistry

Volumn 51, Issue 23, 2008, Pages 7532-7540

  Beierlein, Jennifer M ^a   Frey, Kathleen M ^a   Bolstad, David B ^a   Pelphrey, Phillip M ^a   Joska, Tammy M ^a   Smith, Adrienne E ^b   Priestley, Nigel D ^b   Wright, Dennis L ^a   Anderson, Amy C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE INHIBITOR; METHOTREXATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRIMETHOPRIM;

ARTICLE; BACILLUS ANTHRACIS; CRYSTAL STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LIGANDS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 57349181229     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800776a     Document Type: Article

References (24)

1. Mock, M.; Fouet, A. Anthrax. Annu. Rev. Microbiol. 2001, 55, 647-671.
2. Coker, P.; Smith, K.; Hugh-Jones, M. Antimicrobial susceptibilities of diverse Bacillus anthracis isolates. Antimicrob. Agents Chemother. 2002, 46, 3843-3845.
3. Davidson, R.; Cavalcanti, R.; Brunton, J.; Bast, D.; DeAzavedo, J.; Kibsey, P.; Fleming, C.; Low, D. Resistance to levofloxacin and failure of treatment of Pneumococcal pneumonia. N. Engl. J. Med. 2002, 346, 747-750.
4. Neuhauser, M.; Weinstein, R.; Rydman, R.; Danziger, L.; Karam, G.; Quinn, J. Antibiotic resistance among gram-negative Bacilli in US intensive care units. JAMA, J. Am. Med. Assoc. 2003, 289, 885-888.
5. Barrow, E.; Bourne, P.; Barrow, W. Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim. Antimicrob. Agents Chemother. 2004, 48, 4643-4649.
6. Sirotnak, F.; Burchall, J.; Ensminger, W.; Montgomery, J. Folate Antagonists as Therapeutic Agents; Academic Press: New York, 1984.
7. Fleming, G.; Schilsky, R. Antifolates: the next generation. Semin. Oncol. 1992, 19, 707-719.
8. Salter, A. Trimethoprim-sulfamethoxazole: an assessment of more than 12 years of use. Rev. Infect. Dis. 1982, 4, 196-236.
9. Roth, B.; Rauckman, B.; Ferone, R.; Baccanari, D.; Champness, J.; Hyde, R. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes. J. Med. Chem. 1987, 30, 348-356.
10. Plowe, C.; Kublin, J.; Dzinjalamala, F. K.; Kamwendo, D.; Mukadam, R.; Chimpeni, P.; Molyneux, M.; Taylor, T.; Terrie, E. Sustained efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first-line treatment: five-year prospective study. Br. Med. J. 2004, 328, 545-8.
11. Armstrong, C.; Smith, C. Cyclization and N-dealkylation of chloroguanide by rabbit and rat hepatic microsomes. Toxicol. Appl. Pharmacol. 1974, 29, 90.
12. Rosowsky, A.; Forsch, R.; Queener, S. Further studies on 2,4-diamino-5-(2′,5′-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J. Med. Chem. 2003, 46, 1726-1736.
13. Bertino, J. Karnofsky memorial lecture: ode to methotrexate. J. Clin. Oncol. 1993, 11, 5-14.
14. Joska, T.; Anderson, A. Structure-activity relationships of Bacillus cereus and Bacillus anthracis dihydrofolate reductase: toward the identification of new potent drug leads. Antimicrob. Agents Chemother. 2006, 50, 3435-3443.
15. Bennett, B.; Xu, H.; Simmerman, R.; Lee, R.; Dealwis, C. Crystal structure of the anthrax drug target Bacillus anthracis dihydrofolate reductase. J. Med. Chem. 2007, 50, 4374-4381.
16. Pelphrey, P.; Popov, V.; Joska, T.; Beierlein, J.; Bolstad, E.; Fillingham, Y.; Wright, D.; Anderson, A. Highly efficient ligands for DHFR from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. J. Med. Chem. 2007, 50, 940-950.
17. Chan, D.; Anderson, A. Towards species-specific antifolates. Curr. Med. Chem. 2006, 13, 377-398.
18. Bates, P.; Kelley, L.; MacCallum, R.; Sternberg, M. Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins 2001, 45 (S5), 39-46.
19. Anderson, A. Two crystal structures of dihydrofolate reductase- thymidylate synthase from Cryptosporidium hominis reveal protein: ligand interactions including a structural basis for observed antifolate resistance. Acta Crystallogr. 2005, F61, 258-262.
20. Bolin, J.; Filman, D.; Matthews, D.; Hamlin, R.; Kraut, J. Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 Å resolution. I. General features and binding of methotrexate. J. Biol. Chem. 1982, 257, 13650-13662.
21. Cody, V.; Schwalbe, C. Structural characteristics of antifolate dihydrofolate reductase enzyme interactions. Crystallogr. Rev. 2006, 12, 301-333.
22. Yuvaniyama, J.; Chitnumsub, P.; Kamchonwongpaisan, S.; Vanichtanankul, J.; Sirawarapom, W.; Taylor, P.; Walkinshaw, M.; Yuthavong, Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat. Struct. Biol. 2003, 10, 357-365.
23. Richardson, M. L.; Stevens, M. F. G. Structural studies on bioactive compounds. Part 37. Suzuki coupling of diaminopyrimidines: a new synthesis of the antimalarial drug pyrimethamine. J. Chem. Res., Synop. 2002, 10, 482.
24. Roth, B.; Aig, E.; Lane, K.; Rauckman, B. S. 2,4-Diamino-5- benzylpyrimidines as antibacterial agents. 4. 6-Substituted trimethoprim derivatives from phenolic Mannich intermediates. Application to the synthesis of trimethoprim and 3,5-dialkylbenzyl analogs. J. Med. Chem. 1980, 23 (5), 535-541.